These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 20685631)
21. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791 [TBL] [Abstract][Full Text] [Related]
22. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections. Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673 [TBL] [Abstract][Full Text] [Related]
23. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S; Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291 [TBL] [Abstract][Full Text] [Related]
24. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Höffken G; Barth J; Rubinstein E; Beckmann H; Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211 [TBL] [Abstract][Full Text] [Related]
25. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. Lloyd A; Holman A; Evers T Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083 [TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166 [TBL] [Abstract][Full Text] [Related]
27. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Simoens S Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752 [TBL] [Abstract][Full Text] [Related]
28. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Martin M; Moore L; Quilici S; Decramer M; Simoens S Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196 [TBL] [Abstract][Full Text] [Related]
29. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia]. Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672 [TBL] [Abstract][Full Text] [Related]
30. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. Lipsky BA; Giordano P; Choudhri S; Song J J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812 [TBL] [Abstract][Full Text] [Related]
31. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Wispelwey B; Schafer KR Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291 [TBL] [Abstract][Full Text] [Related]
32. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032 [TBL] [Abstract][Full Text] [Related]
33. Moxifloxacin: a respiratory fluoroquinolone. Miravitlles M; Anzueto A Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608 [TBL] [Abstract][Full Text] [Related]
34. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment. Wenisch C; Krause R; Széll M; Laferl H Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576 [TBL] [Abstract][Full Text] [Related]
35. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A; Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. Xu S; Xiong S; Xu Y; Liu J; Liu H; Zhao J; Xiong W J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):421-4. PubMed ID: 17120738 [TBL] [Abstract][Full Text] [Related]
37. Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects. Bassetti M; Rosso R; Tosi C; DI Biagio A; Righi E; Viscoli C J Chemother; 2007 Feb; 19(1):104-5. PubMed ID: 17309861 [No Abstract] [Full Text] [Related]
38. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Ferrara AM Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134 [TBL] [Abstract][Full Text] [Related]
39. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Petitpretz P; Arvis P; Marel M; Moita J; Urueta J; Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603 [TBL] [Abstract][Full Text] [Related]
40. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]